Sagimet Biosciences dropped 9% after Ascletis Pharma’s Phase 3 Denifanstat safety data focused on tolerability, not new efficacy, spurring investor caution. SGMT’s Denifanstat, a first-in-class FASN ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results